{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:13:33Z","timestamp":1790957613209,"version":"4.1.0"},"reference-count":88,"publisher":"Baishideng Publishing Group Inc.","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJP"],"published-print":{"date-parts":[[2021,7,19]]},"DOI":"10.5498\/wjp.v11.i7.355","type":"journal-article","created":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T03:32:23Z","timestamp":1626319943000},"page":"355-364","source":"Crossref","is-referenced-by-count":56,"title":["History of the dopamine hypothesis of antipsychotic action"],"prefix":"10.5498","volume":"11","author":[{"given":"Mary V","family":"Seeman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-clinpsy-050718-095514"},{"key":"B2","unstructured":"Laborit H. [Neuro-vegetative therapy for shock and post-traumatic disease]. Presse Med 1949; 58: 138-140"},{"key":"B3","unstructured":"Charpentier P, Gailliot P, Jacob R, Gaudechon J, Buisson P. [Research on substituted dimethylaminopropyl-N phenothiazines]. C R Acad Sci III (Paris)  1952; 235: 59-60"},{"key":"B4","unstructured":"Laborit H, Huguenard P, Alluaume R. [A new vegetative stabilizer; RP4560]. Presse Med 1952; 60: 206-208"},{"key":"B5","unstructured":"Hamon, Paraire, Velluz. [Effect of RP4560 on maniacal agitation]. Ann Med Psychol (Paris) 1952; 110: 331-335"},{"key":"B6","unstructured":"Delay J, Deniker P. [Prolonged and continuous treatment of psychosis by a neuroleptic method solely  derived from hibernotherapy]. CR Congr M\u00e9d Ali\u00e9n Neurol 1952; 50: 497-502"},{"key":"B7","unstructured":"Delay J, Deniker P, Harl JM. [Therapeutic use in psychiatry of phenothiazine of central elective action (RP4560 )]. Ann Med Psychol (Paris) 1952; 110: 112-117"},{"key":"B8","unstructured":"Broggi E. [Results of the national convention held at Vercelli on September 24-25 on artificial hibernation, prolonged sleep and tranquilizing agents in neuropsychiatry]. Encephale 1956; 45: 1035-1041"},{"key":"B9","unstructured":"Navarrane P, Picard P. [Some reflections on the applications of artificial hibernation in neuro-psychiatry]. Encephale 1956; 45: 456-457"},{"key":"B10","unstructured":"Neveu P. [Hibernation, emergency treatment of syndromes of decompensated shock in psychiatry]. Encephale 1956; 45: 377-381"},{"key":"B11","unstructured":"Delay J, Deniker P, Harl JM. [Therapeutic method derived from hibernotherapy in excitation and agitation states]. Ann Med Psychol (Paris) 1952; 110: 267-273"},{"key":"B12","unstructured":"Ban TA. Fifty years chlorpromazine: a historical perspective. Neuropsychiatr Dis Treat 2007; 3: 495-500"},{"key":"B13","unstructured":"Koeppe R.   Largactil\u2014some preliminary clinical observations. Meeting of the Ontario Neuropsychiatric Association at Ontario Hospital; 27 November 1953; Whitby (ON), 1953"},{"key":"B14","doi-asserted-by":"crossref","unstructured":"Lehmann HE, Hanrahan GE. Chlorpromazine; new inhibiting agent for psychomotor excitement and manic states. AMA Arch Neurol Psychiatry 1954; 71: 227-237","DOI":"10.1001\/archneurpsyc.1954.02320380093011"},{"key":"B15","unstructured":"Saucier R, Fischmeister LV. L\u2019emploi du Largactil en psychiatrie. [The use of Largactil in psychiatry]. Saguenay M\u00e9dical 1954; 3: 226-231"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1021\/jm50004a007"},{"key":"B17","unstructured":"Berger FM. The pharmacological properties of 2-methyl-2-n-propyl-1,3-propanediol dicarbamate (Miltown), a new interneuronal blocking agent. J Pharmacol Exp Ther 1954; 112: 413-423"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1963.tb01730.x"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/BF01485901"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(64)90012-7"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.106.442.337"},{"key":"B22","doi-asserted-by":"crossref","unstructured":"Connell PH. Amphetamine psychosis. Br Med J 1957; 1: 582","DOI":"10.1136\/bmj.1.5018.582"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1951.72920250003008a"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/BF01900988"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1965.tb07646.x"},{"key":"B26","unstructured":"van Rossum JM. The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Ther 1966; 160: 492-494"},{"key":"B27","unstructured":"van Rossum JM.   In: Proceedings of the fifth international congress of the Collegium Internationale neuro-psycho-pharmacologicum, Washington, DC. March 1966 (Brill H. ed.), Excerpta Medica Foundation, Amsterdam, 1967: 321-329."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1353\/ppp.2011.0005"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.130.1.61"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.148.11.1474"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbp006"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5949.2010.00162.x"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.107704"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/s0021-9673(01)80240-5"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.4088\/pcc.v05n0202"},{"key":"B36","unstructured":"Humber LG, Bruderlein F.   Butaclamol hydrochloride, a novel neuroleptic agent. Part I Synthesis and stereochemistry. Proceedings of the 167th American Chemical Society Meeting for Medicinal Chemistry, abstract #5, American Chemical Society, Washington. DC, 1974."},{"key":"B37","unstructured":"Voith K.   Butaclamol hydrochloride, a novel neuroleptic agent. Part II Pharmacology. Proceedings of the 167th American Chemical Society Meeting for Medicinal Chemistry, abstract #6, American Chemical Society, Washington, DC, 1974."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.72.11.4376"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1126\/science.1145194"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/261717a0"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.663245"},{"key":"B42","unstructured":"Burt DR, Creese I, Snyder SH. Properties of [3H]haloperidol and [3H]dopamine binding associated with dopamine receptors in calf brain membranes. Mol Pharmacol 1976; 12: 800-812"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(75)90454-3"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1126\/science.3854"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1126\/science.6147018"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1992.01820070032005"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800250087012"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.156.2.286"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s002130050277"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(93)90288-o"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1017\/s0033291700025575"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbn009"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.146.7.905"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(82)90700-6"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/277093a0"},{"key":"B56","unstructured":"Spano PF, Govoni S, Trabucchi M. Studies on the pharmacological properties of dopamine receptors in various areas of the central nervous system. Adv Biochem Psychopharmacol 1978; 19: 155-165"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.01003"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1210\/endo-117-2-690"},{"key":"B59","unstructured":"Wreggett KA, Seeman P. Agonist high - and low-affinity states of the D2-dopamine receptor in calf brain. Partial conversion by guanine nucleotide. Mol Pharmacol 1984; 25: 10-17"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/347080a0"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/350610a0"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/350614a0"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/336783a0"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.24.9762"},{"key":"B65","unstructured":"Grandy DK, Litt M, Allen L, Bunzow JR, Marchionni M, Makam H, Reed L, Magenis RE, Civelli O. The human dopamine D2 receptor gene is located on chromosome 11 at q22-q23 and identifies a TaqI RFLP. Am J Hum Genet 1989; 45: 778-785"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/2.1.19"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/347146a0"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/17.2.263"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2011.02.007"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2004.04.020"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.156.6.876"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-012-0734-2"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.202498299"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e32833ee605"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/s0169-328x(99)00343-5"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-59745-205-2_8"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyx063"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1002\/syn.890170107"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.01.027"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.1c00094"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/s0165-0173(99)00043-0"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-016-4382-y"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2005.07.017"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1186\/s13041-017-0293-z"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2010.09.110"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2013.11.104"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2010.08.010"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00591"}],"container-title":["World Journal of Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/2220-3206\/full\/v11\/i7\/355.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T05:11:40Z","timestamp":1626325900000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/2220-3206\/full\/v11\/i7\/355.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,19]]},"references-count":88,"journal-issue":{"issue":"7"},"URL":"https:\/\/doi.org\/10.5498\/wjp.v11.i7.355","relation":{},"ISSN":["2220-3206"],"issn-type":[{"value":"2220-3206","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,19]]}}}